FDA Plays

[colorofmoney]

Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com

* Press Release
* Source: StockPreacher
* On 4:30 pm EST, Thursday November 12, 2009

Companies:
o Bioelectronics Corporation
o Johnson Johnson
o Pfizer Inc.

DALLAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring BioElectronics Corporation (Pink Sheets:BIEL - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
Related Quotes
Symbol Price Change
BIEL.PK 0.0870 -0.0052
Chart for BIOELECTRONICS CORP
{"s" : "biel.pk,jnj,pfe","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on BioElectronics Corporation (Pink Sheets:BIEL - News) should be of particular interest to comparable healthcare products providers: Johnson & Johnson (NYSE:JNJ - News), Pfizer (NYSE:PFE - News) and Bayer Aktienges (Pink Sheets:BAYRY - News).

The full report is available at: http://www.stockpreacher.com/n/BIEL

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

BioElectronics Corporation is the maker of innovative, patented, drug-free, over-the-counter, anti-inflammation medical devices and patches. The Company's novel approach to pain relief includes a wafer-thin patch containing a microchip and battery that produces pulsed electromagnetic energy, which has proved as an effective and superior method of safe relief of inflammation and pain following injury or invasive medical procedures. The Company markets its present products under the brand names ActiPatch(TM) and RecoveryRX(TM).

Message Board Search for BIEL: http://www.boardcentral.com/boards/BIEL

In the report, the analyst notes:

"The Company's dermal patch pain relief system is an innovative approach to anti-inflammation, which is estimated to address an approximate 400 million number of incidents of acute inflammation conditions each year. The market for anti-inflammation products is anticipated to grow beyond the current $10 billion market worldwide.

"The Company's products have entered Food and Drug Administration (FDA) clinical trials for various and wide number of conditions which have high probabilities of approval. Data released by the Company for the relief of heal and foot pain show a high degree of efficacy, providing widespread optimism and speculation of imminent FDA approval of the Company's Allay(TM) product. According to research firm Alquemie Partners LLC, approval of Allay(TM) could increase the Company's market capitalization to between $300 million and $500 million."

To read the entire report visit: http://www.stockpreacher.com/n/BIEL

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

Contact:

StockPreacher.com
Jeff Bishop
(469)-252-3505
[e-mail]